Fortress Biotech Inc. (FBIO) had a rough trading day for Tuesday April 16 as shares tumbled 7.74%, or a loss of $-0.12 per share, to close at $1.43. After opening the day at $1.54, shares of Fortress Biotech Inc. traded as high as $1.58 and as low as $1.41. Volume was 426,092 shares over 2,110 trades, against an average daily volume of n/a shares and a total float of 61.3 million.
As a result of the decline, Fortress Biotech Inc. now has a market cap of $87.66 million. In the last year, shares of Fortress Biotech Inc. have traded between a range of $4.53 and $0.49, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Fortress Biotech Inc. is based out of New York, NY and has some 88 employees. Its CEO is Lindsay A. Rosenwald.